Beijing Neox Biotech Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-targeting moiety covalently bound to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of cancer.

Glenmark Pharmaceuticals Ltd. has disclosed E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders.

Shanghai Allist Pharmaceuticals Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders.

Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases.

Researchers at the Japanese Foundation for Cancer Research and RIKEN have disclosed tankyrase 1 (TNKS1; PARP5A) and/or TNKS2 (PARP5B) inhibitors reported to be useful for the treatment of cancer, metabolic disease, cartilage injury, multiple sclerosis, pulmonary fibrosis, amyotrophic lateral sclerosis, herpes simplex virus and Epstein Barr virus infections.

Kymera Therapeutics Inc. has described proteolysis targeting chimeras (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)-targeting moiety through a linker.

Fochon Biosciences Ltd. has divulged apoptosis regulator Bcl-2 (D103E mutant and D103Y mutant) inhibitors reported to be useful for the treatment of autoimmune disease and cancer.